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Abstract
Background: Declines in prostate-specific antigen (PSA) levels at 12 wk are used to
evaluate treatment response in metastatic castration-resistant prostate cancer
(mCRPC). PSA fall by 30% at 4 wk (PSA4w30) has been reported to be associated
with better outcome in a single-centre cohort study.
Objective: To evaluate clinical relevance of early PSA decline in mCRPC patients
treated with next-generation hormonal treatments (NGHTs) such as abiraterone
and enzalutamide.
Design, setting, and participants: This was a retrospective multicentre analysis.
Eligible patients received NGHT for mCRPC between 6 January 2006 and 31 De-
cember 2017 in 13 cancer centres worldwide, and had PSA levels assessed at
baseline and at 4 and/or 12 wk after treatment. PSA response was defined as a 30%
decline (progression as a 25% increase) from baseline.
Outcome measurements and statistical analysis: Association with overall survival
(OS) was analysed using landmark multivariable Cox regression adjusting for
previous chemotherapy, including cancer centre as a shared frailty term.
Results and limitations: We identified 1358 mCRPC patients treated with first-line
NGHT (1133 had PSA available at 4 wk, and 948 at both 4 and 12 wk). Overall, 5830; 
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interval [CI]: 21–25) compared with no change (median: 17; 95% CI: 15–18) and
progression (median: 13; 95% CI: 10–15). A PSA12w30 was associated with lower
mortality (median OS 22 vs 14; hazard ratio = 0.57; 95% CI = 0.48–0.67; p < 0.001).
PSA4w30 strongly correlated with PSA12w30 (r = 0.91; 95% CI = 0.90–0.92;
p < 0.001). In total, 432/494 (87%) with a PSA4w30 achieved a PSA12w30. Overall,
11/152 (7%) patients progressing at 4 wk had a PSA12w30 (1% of the overall popula-
tion).
Conclusions: PSA changes in the first 4 wk of NGHT therapies are strongly associ-
ated with clinical outcome from mCRPC and can help guide early treatment switch
decisions.
Patient summary: Prostate-specific antigen changes at 4 wk after abiraterone/
enzalutamide treatment are important to determine patients’ outcome and should
be taken into consideration in clinical practice.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Prostate-specific antigen (PSA) is still widely used for
diagnosis and treatment evaluation of prostate cancer [1,2],
with the consensus criteria of the Prostate Cancer Working
Group (PCWG3) defining response to treatment and
progression based on composite measures of clinical,
radiologic, and PSA changes [3]. PCWG3 criteria suggest
reporting PSA response as waterfall plots; however, a 30%
PSA decline at 12 wk after treatment initiation has strongly
been associated with improved overall survival (OS) from
metastatic castration-resistant prostate cancer (mCRPC) [4–
6]. Conversely, PSA progression, defined as a 25% increase
from baseline/nadir, has been correlated with a poor
outcome [7,8]. More recently, PSA kinetics has been
reported to meet OS surrogacy criteria [9]. Evaluation of
PSA earlier than 12 wk from treatment initiation has
traditionally been discouraged because of the possibility
of late responses and flare reactions in patients [3,10,11]
treated with taxanes.
We have previously reported a single-institution retro-
spective study showing that early falls in PSA by 30% after
4 wk of treatment with abiraterone acetate (AA), this being
a pharmacodynamic measure of androgen receptor block-
ade, are associated with improved OS as well as biochemical
responses after 12 wk in both the pre- and the postche-
motherapy setting, with PSA “flares” being rare after AA
[12]. In the present analyses, we report on an international
study involving 13 cancer centres evaluating the association
between early PSA changes (after 4 wk of treatment) and
outcomes from mCRPC after AA and enzalutamide. We
envisioned that early PSA changes could help facilitate
earlier treatment switch decisions.
2. Patients and methods
2.1. Study design and data collection
Patients with biochemically or histologically confirmed progressive
mCRPC and castrate levels of testosterone treated with AA and/orenzalutamide outside of a clinical trial between 06 January 2006 and
31 December 2017 in 13 cancer centres worldwide were considered
eligible for this analysis. Additional inclusion criteria were the
availability of PSA levels assessed at baseline, and after 4 and/or
12 wk of treatment; a physical examination, including Eastern Coopera-
tive Oncology Group performance status; and routine safety blood test
laboratory studies, including a full blood count (haemoglobin, neutro-
phil, and lymphocyte count) and biochemistry comprising alkaline
phosphatase (ALP), and lactate dehydrogenase (LDH) at baseline and
during treatment. Every institution has received ethic board approval for
the treatment of patient data. All patients’ data were anonymised and
handled according to the Data Protection Act.
2.2. Endpoint definition
OS was defined as the time between treatment initiation and the date of
either death or the last follow-up for surviving patients.
PSA decline endpoints evaluated were consistent with published
consensus guidelines (PCWG3). The percentage change in PSA from
baseline at 4 and 12 wk was categorised as a decline (30% decrease),
progression (25% increase), or no change. A PSA reading not meeting
the criteria of either response or progression was considered as “no
change”.
2.3. Statistical analysis
Baseline characteristics are compared by chemotherapy status. Differ-
ences by chemotherapy status in categorical characteristics were tested
using Fisher’s exact test and continuous variables were compared using
the Wilcoxon rank-sum test. The Kaplan-Meier method and landmark
multivariable Cox models were used to assess for differences in OS,
including cancer treatment centre as a shared frailty term. The
multivariable Cox model included categorical PSA change; chemothera-
py status; treatment; Gleason index; tumour, node, and metastasis status
at diagnosis; opiate use at the start of treatment; haemoglobin; ALP;
LDH; and neutrophil-lymphocyte ratio (NLR). Haemoglobin, LDH, ALP,
and NLR were log transformed. Approximately 70% of patients were
missing one or more of these characteristics. To avoid a loss in efficiency
in the multivariable analysis, multiple imputation by chained equations
was used to generate 40 imputations, and per-imputation estimates
were combined using Rubin’s rules. A multivariable fractional polyno-
mial Cox model was used to determine the association of OS with
continuous change in PSA and the previously specified multivariable
Table 1 – Baseline characteristics.
Characteristic Prechemotherapy
(N = 530)
Postchemotherapy
(N = 603)
p valuea Total (N = 1133)
N % N % N %
PSA change at week 4
No change 156 29 188 31 0.75 344 30
Progression 95 18 111 18 – 206 18
Decline 279 53 304 50 – 583 52
Gleason score at diagnosis
<8 250 47 269 45 0.70 519 46
8 212 40 252 42 – 464 41
Missing 68 13 82 14 – 150 13
M status at diagnosis
M0 243 46 226 38 0.01 469 41
M1 261 49 351 58 – 612 54
Missing 26 5 26 4 – 52 5
N status at diagnosis
N0 232 44 196 33 <0.001 428 38
N1 110 20.8 168 28 – 278 26
Missing 188 36 239 40 – 427 38
T status at diagnosis
T < 3 131 25 122 21 <0.001 253 22
T  3 243 46 222 37 – 465 41
Missing 156 29 259 43 – 415 37
Opiates at start of NGHT
No 417 79 328 54 <0.001 745 66
Yes 94 18 256 43 – 350 31
Missing 19 4 19 3 – 38 3
Metastatic disease at start of NGHT
Bone 244 46 224 37 <0.001 468 41
LND 78 15 50 8 – 128 11
Visc 5 1 6 1 – 11 1
Bone + LND 140 26 226 38 – 366 32
Bone + Visc 16 3 26 4 – 42 4
LND + Visc 6 1 11 2 – 17 2
Bone + LND + Visc 35 7 58 10 – 93 8
Missing 7 1 1 0 – 8 1
Lab values at start of NGHT Median IQR Median IQR p valueb Median IQR
PSA 56 20–132 99 30–339 <0.001 73 25–234
Hb 12 11–13 12 10–13 <0.001 12 11–13
ALP 108 75–182 139 77–307 <0.001 117 76–233
LDH 206 164–302 213 172–332 0.03 210 168–317
NLR 3 2–4 3 2–4 0.2 3 2–4
ALP = alkaline phosphatase; Hb = haemoglobin; IQR = interquartile range; LDH = lactate dehydrogenase; LND = lymph node disease; NGHT = next-generation
hormonal treatment; NLR = neutrophil-lymphocyte ratio; PSA = prostate-specific antigen; Visc = visceral disease.
a Fisher’s exact test.
b Wilcoxon rank-sum test.
Table 2 – Relationship between week-4 and week-12 PSA changes
for patients on first regimen of abiraterone acetate or
enzalutamide.
PSA change at week 4 PSA change at week 12
No change Progression Decline
No change 113 (37%) 100 (33%) 89 (29%)
Progression 19 (13%) 122 (80%) 11 (7%)
Decline 48 (10%) 14 (3%) 432 (87%)
PSA = prostate-specific antigen.
E U R O P E A N U R O L O G Y O N C O L O G Y 3 ( 2 0 2 0 ) 17 6 – 18 2178covariates. The cancer treatment centre could not be included in this
model as a shared frailty term and so was included as a categorical
covariate.
3. Results
We identified 1358 patients treated with either AA or
enzalutamide as a first-line hormonal agent for mCRPC in
the pre- or post-chemotherapy settings. A total of
1133 patients had a PSA result available after 4 wk with
survival data, while 948 had PSA results available at both 4-
and 12-wk time points; of these, 938 had survival data. The
overall patient characteristics are summarised in Table 1;
583 of 1133 (52%) patients had a 30% PSA decline at 4 wk.
Out of the 948 patients with PSA results available at both
4 and 12 wk, 432 of 494 (87%) patients achieved a PSAdecline at 4 and 12 wk. PSA at 4 and 12 wk were strongly
correlated (r = 0.91; 95% confidence interval [CI]: 0.90–
0.92; p < 0.001). Conversely, 11 of 152 (7%) patients
progressing by PSA at 4 wk, which represented 1.1% of
Fig. 1 – Kaplan-Meier curves of overall survival by change in PSA at 4 wk. CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen.
Table 3 – Landmark (week 4) multivariable Cox model for
association with overall survival.
n % HR 95% CI p value
PSA change after 4 wk
No change 344 30 1.00 – <0.001
Progression 206 18 1.38 0.99–1.94 –
Decline 583 52 0.67 0.51–0.88 –
Chemotherapy status
Prechemotherapy 531 47 1.00 – <0.001
Postchemotherapy 602 53 1.67 1.26–2.22 –
PSA change  chemotherapy status
No change and postchemotherapy 188 31 1.00 – 0.75
Progression and postchemotherapy 111 18 0.87 0.57–1.34 –
Decline and postchemotherapy 303 50 0.89 0.63–1.25 –
Treatment
Abiraterone 911 80 1.00 – 0.13
Enzalutamide 222 20 0.84 0.67–1.05 –
Gleason Index at diagnosis
<8 519 53 1.00 – 0.86
8 464 47 1.02 0.85–1.22 –
M status at diagnosis
M0 469 43 1.00 – 0.79
M1 612 57 1.02 0.86–1.22 –
N status at diagnosis
N0 428 61 1.00 – 0.44
N1 278 39 1.08 0.88–1.32 –
T status at diagnosis
T <3 253 35 1.00 – 0.89
T 3 465 65 0.98 0.80–1.21 –
Opiates at start of treatment
No 745 68 1.00 – <0.001
Yes 350 32 1.46 1.22–1.73 –
Lab values at start of treatment Med IQR HR 95% CI p value
Hb (log10 g/dl) 1.08 1.02–1.11 0.95 0.62–1.46 0.8
ALP (log10 U/l) 2.07 1.88–2.37 2.28 1.86–2.81 <0.001
LDH (log10 U/l) 2.32 2.23–2.50 1.62 1.14–2.28 0.007
NLR (log10) 0.48 0.30–0.62 1.57 1.12–2.20 0.008
ALP = alkaline phosphatase; CI = confidence interval; Hb = haemoglobin;
HR = hazard ratio; IQR = interquartile range; LDH = lactate dehydrogenase;
NLR = neutrophil-lymphocyte ratio; PSA = prostate-specific antigen.
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at 12 wk (Table 2).
A 30% PSA decline at 4 wk was associated with longer
OS (median: 23 mo; 95% CI: 21–25) compared with patients
with no change (median: 17; 95% CI: 15–18) and progression
(median: 13 mo; 95% CI: 10–15; Fig. 1). The results from
multivariable Cox models, adjusting for known prognostic
factors from mCRPC such as ALP, LDH, and NLR, are shown in
Table 3. Patients with a 30% PSA decline at 4 wk had a
reduced incidence of mortality compared with patients
with no change (adjusted hazard ratio [aHR]: 0.67; 95% CI:
0.51–0.88, p < 0.001); there was no statistically significant
evidence of a difference in terms of reduced mortality for
patients with a 25% increase compared with patients with
no change (aHR: 1.38; 95% CI: 0.99–1.94). The results at 12-
wk time point were similar, with a 30% PSA decline
associated with longer OS (median: 22 mo; 95% CI: 19–24;
HR: 0.71, 95% CI: 0.50–1.02, p < 0.001) compared with
patients with no change (median: 16 mo; 95% CI: 12–18)
and progression (median: 11 mo; 95% CI: 8–13; Fig. 2).
When abiraterone and enzalutamide groups were consid-
ered separately, there was no evidence that the association
between OS and PSA falls differed by first-line treatment.
The multivariable Cox model results are shown in Table 4;
there was no formal evidence of a difference in survival for
patients with no change at 12 wk compared with those with
a 30% decline (HR: 0.71; 95% CI: 0.50–1.02) or a 25%
increase (HR: 1.44; 95% CI: 0.97–2.14).
The results from the multivariable analyses studying PSA
change as a continuous variable are displayed in Supple-
mentary Tables 1 and 2, and Supplementary Figures 1 and 2.
3.1. Performance on second hormonal agent after AA/
enzalutamide
The PSA response rate at 4 and 12 wk for the second
regimen of AA or enzalutamide was available for
Fig. 2 – Kaplan-Meier curves of overall survival by change in PSA at 12 wk. CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen.
Table 4 – Landmark (week 12) multivariable Cox model for
association with overall survival.
n % HR 95% CI p value
PSA change at week 12
No change 179 19 1.00 – <0.001
Progression 231 25 1.44 0.99–2.14 –
Decline 528 56 0.71 0.50–1.02 –
Chemotherapy status
Prechemotherapy 426 45 1.00 – 0.006
Postchemotherapy 512 55 1.73 1.17–2.57 –
PSA change at week 12  chemotherapy status
No change and postchemotherapy 103 20 1.00 – 0.4
Progression and postchemotherapy 134 26 0.97 0.59–1.59 –
Decline and postchemotherapy 275 54 0.79 0.50–1.24 –
Treatment
Abiraterone 756 81 1.00 – 0.1
Enzalutamide 182 19 0.81 0.63–1.05 –
Gleason Index at diagnosis
<8 435 53 1.00 – 0.9
8 383 47 1.01 0.82–1.23 –
M status at diagnosis
M0 405 45 1.00 – 0.9
M1 495 55 0.99 0.82–1.19 –
N status at diagnosis
N0 369 61 1.00 – 0.7
N1 236 39 1.05 0.84–1.31 –
T status at diagnosis
T <3 216 36 1.00 – 0.9
T 3 390 64 1.01 0.80–1.28 –
Opiates at start of treatment
No 616 68 1.00 – <0.001
Yes 294 32 1.42 1.18–1.71 –
Lab values at start of treatment Med IQR HR 95% CI p value
Hb (log10 g/dl) 1.08 1.02–1.11 0.90 0.54–1.51 0.7
ALP (log10 U/l) 2.07 1.89–2.36 2.15 1.72–2.70 <0.001
LDH (log10 U/l) 2.32 2.23–2.50 1.50 1.08–2.09 0.02
NLR (log10) 0.48 0.30–0.61 1.76 1.21–2.56 0.003
ALP = alkaline phosphatase; CI = confidence interval; Hb = haemoglobin;
HR = hazard ratio; IQR = interquartile range; LDH = lactate dehydrogenase;
NLR = neutrophil-lymphocyte ratio; PSA = prostate-specific antigen.
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30% at 4 wk was observed in 42/168 (25%) patients and
that at 12 wk was observed in 42/168 (25%) patients. There
was less concordance between observed PSA declines on
second next-generation hormonal treatment (NGHT). Over-
all, 29/42 (69%) patients with a PSA decline at 4 wk had a
PSA decline at 12 wk. There was no evidence in a univariable
logistic regression model that the time on previous NGHT
was associated with a PSA decline of 30% at 12 wk (odds
ratio = 0.93 per year on treatment; 95% CI: 0.56–1.54;
p = 0.77).
Finally, the results from the multivariable analyses
studying PSA changes at both week 4 and week 12 are
displayed in Supplementary Table 4, and indicate that the
presence of a 30% PSA fall at 4 wk confirmed at 12 wk
associates with superior OS when compared with all the
other possible PSA outcomes.
4. Discussion
Evaluation of responses to treatment for mCRPC remains
challenging. In the localised setting, a PSA increase of
>0.5 ng/ml after prostatectomy or 2 ng/ml above the nadir
after radical radiotherapy has been proved to be a sensitive
biomarker to identify men who are at a high risk of relapse
or death [13,14]. On the contrary, in the metastatic setting,
consensus criteria based on PSA and radiologic biomarkers
are inconsistently utilised. A recent study inquiring into
clinical management decisions of physicians in mCRPC has
shown that despite being considered an important bio-
marker, 41.4% of the interviewed population disregarded
changes in PSA before 12 wk of treatment had elapsed,
while the majority of physicians (90.5%) switched treatment
based only on clinical progression [15].
A PSA decline by 30% after 12 wk of treatment start has
been associated with OS in mCRPC [4–6]; more recently, PSA
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for treatment switch in the TAXYNERGY study [16]. In this
study, PSA declines were associated with taxane responses,
and decreased androgen receptor nuclear localisation and
increased microtubule bundling in circulating tumour cells
[16]. Nevertheless, PCWG3 criteria have discouraged treat-
ment decisions based on early PSA changes, since flare
reactions within the first 12 wk of treatment have been
described in approximately a third of patients treated with
docetaxel and cabazitaxel [3,10,11]. In our previously reported
single-centre retrospective analysis, on a cohort of 274 mCRPC
patients treated at the Royal Marsden Hospital, we have
reported that a 30% PSA decline at 4 wk was associated with
longer OS, significantly correlating with PSA falls at 12 wk
[12]. In the current analysis, we have collected survival data
for 1133 mCRPC patients treated with AA or enzalutamide
(NGHT) in 13 cancer centres worldwide. We have confirmed
the clinical relevance and prognostic value of early PSA
declines in patients treated with NGHT before or after
chemotherapy. Unlike chemotherapy, in this study, we can
confirm that an early PSA flare, defined as an increase of >25%
in the first 4 wk followed by a decline of >30% from baseline
at wk 12, is very uncommon following AA and enzalutamide,
involving only 1% of the overall population treated with
NGHT. These data corroborate our previous single-centre
analyses and other experiences on patients treated with AA
[12].
Our results may also be important to the hormone-
sensitive prostate cancer (HSPC) setting. In the LATITUDE
study, a prospective randomised phase 3 trial randomising
newly diagnosed metastatic HSPC men to either AA and
androgen deprivation therapy (ADT) or placebo and ADT,
investigators showed that PSA response and time to PSA nadir
correlated with radiographic progression-free survival and
OS. Patients who reached their PSA nadir in <6 mo had a
median time to death of 29.57 mo, while patients who
achieved a PSA nadir after 12 mo or more did not reach the
median time to death [17]. However, the clinical utility of this
biomarker is unclear, as the time to nadir and the depth of
nadir can be determined only retrospectively. The LATITUDE
study included a PSA assessment at week 4; according to our
results, it could be of interest to analyse PSA decline at 4 wk as
a surrogate biomarker of clinical outcome even in this patient
population. Therefore, early identification of patients benefit-
ing from NGHTcould be of paramount importance for optimal
treatment delivery and cost effectiveness in HSPC. Prior
versions of the PCWG criteria were based on mCRPC; new
versions should consider specific surrogate of response and
clinical outcome also in HSPC.
Our study also investigated the likelihood of achieving a
PSA decline from second-line NGHT after prior exposure to
AA or enzalutamide. A 30% PSA reduction was much less
common in this second-line NGHT setting at both 4 and
12 wk compared with patients treated with NGHT as first
line (respectively, 25% vs 51.3% and 25% vs 56.1%). These data
confirm what was previously reported in a multicentre,
single-arm, open-label study, where patients with progres-
sing mCRPC after 24 wk of AA plus prednisone treatment
were enrolled to receive second-line enzalutamide. In thisstudy, the unconfirmed PSA response rate was 27% (48 of
181) with a median time-to-PSA progression of 5.7 mo [18],
demonstrating that second-line enzalutamide has modest
antitumour activity in this selected population [18]. Al-
though less striking, our analyses now show that early PSA
declines are also associated with PSA response at 12 wk in
the setting of second-line NGHT. Therefore, we hypothesise
that the lack of a 30% PSA fall at 4 wk could be used to
discontinue patients from second-line NGHT, saving
patients from time on ineffective therapy and avoiding
the poor utilisation of health-care resources.
Finally, we acknowledge that despite the clinical relevance
of these international multicentre analyses, this study
remains limited by its retrospective nature with a risk of
selection bias and requires validation in prospective studies.
5. Conclusions
PSA changes as early as 4 wk after initiation of NGHT are
significantly associated with OS and PSA response at 12 wk in
both pre- and postchemotherapy settings, while a PSA early
flare after NGHT exposure is very uncommon, according to
our definition. Early PSA changes are also able to predict a
response to second-line NGHT, allowing early treatment
change and avoiding unnecessary therapies, toxicities, and
expenses for patients. Nevertheless, despite our data coming
from a large multicentre population, prospective trials are
now warranted to further validate these findings to obtain
robust evidence for earlier decisions to switch treatment.
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